Compare BRFH & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRFH | BOLD |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.0M | 36.5M |
| IPO Year | 2010 | 2024 |
| Metric | BRFH | BOLD |
|---|---|---|
| Price | $2.54 | $1.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $6.00 | $4.00 |
| AVG Volume (30 Days) | 8.4K | ★ 402.4K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.53 | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $211,467.00 | N/A |
| Revenue This Year | $115.22 | N/A |
| Revenue Next Year | $16.91 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 92.09 | N/A |
| 52 Week Low | $2.30 | $0.96 |
| 52 Week High | $6.08 | $1.72 |
| Indicator | BRFH | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 42.93 | 65.14 |
| Support Level | $2.50 | $1.08 |
| Resistance Level | $3.42 | N/A |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 8.89 | 57.14 |
Barfresh Food Group Inc develops, manufactures and distributes ready to blend frozen beverages, including smoothies, shakes and frappes for restaurant chains and the foodservice industry. The company's proprietary, patented system uses portion-controlled pre-packaged beverage ingredients that deliver freshly made frozen beverages that are quick, cost efficient, and without waste. Barfresh provides both a single serve solution and a bulk format solution, ideal for high-volume locations. It has seven flavors available as part of its standard line vanilla shake, caribbean smoothie, triple berry smoothie, caramel macchiato frappe, strawberry banana smoothie, mocha frappe and mango burst smoothie and has the development capabilities to deliver custom flavors.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.